<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01770483</url>
  </required_header>
  <id_info>
    <org_study_id>SIMS</org_study_id>
    <nct_id>NCT01770483</nct_id>
  </id_info>
  <brief_title>The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</brief_title>
  <acronym>HEP-C-FM</acronym>
  <official_title>The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Services Institute of Medical Sciences, Pakistan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Getz Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Services Institute of Medical Sciences, Pakistan</source>
  <oversight_info>
    <authority>Pakistan: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if nitazoxanide used in combination with
      interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic
      patients by improving their sustained viral response by more than 80%.Considering that the
      study is being conducted in a third world country like Pakistan, the standard treatment of
      hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in
      efficacy to peginterferon and also cost effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After taking proper informed consent from patients, patients who fulfill the research
      criteria are randomized into 2 groups (control/study). Patients in both groups will be
      treated with conventional interferon alfa and Ribavirin.Those in study group will be given
      tab nitazoxanide 500mg twice daily in addition to conventional treatment. The patients will
      be followed up at regular intervals: 0,4,12,24,48 week.At each visit Hepatitis C
      Virus(PCR)RNA, Liver function tests, complete blood count will be done.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Viral Response,</measure>
    <time_frame>48 WEEK</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalization of Alanine Transferase Test</measure>
    <time_frame>48week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Liver function test,showing resolution of the inflammation of liver parenchyma</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>DIABETES MELLITUS Type 2</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitazoxanide</intervention_name>
    <description>nitazoxanide 500mg twice daily</description>
    <arm_group_label>study group</arm_group_label>
    <other_name>tablet nizonide500mg</other_name>
    <other_name>tablet atizox500mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional interferon alfa</intervention_name>
    <description>Inj interferon 3 Million International Units thrice weekly</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Inj uniferon 3 Million International Units</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>ribazole</description>
    <arm_group_label>study group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Ribavirin 400mg-1200mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis C genotype 3a

          -  Hepatitis C Virus(PCR)RNA Detected

          -  Alanine transaminase &gt;60

          -  Diabetic HbA1c&lt;8

          -  BMI&gt;23

        Exclusion Criteria:

          -  Previously treated Hepatitis C patients

          -  Pregnant females

          -  Decompensated liver disease,Child class B OR above

          -  Thyroid disease,Thyroid stimulating hormone&gt;10,0.05

          -  Absolute neutrophil count&lt;1500,Platelets&lt;80,000,Hb&lt;10g Female,&lt;11g Male

          -  Severe cardiac disease,New York Heart Association2

          -  Moderate to severe depression assessed by Beck Depression Inventory scale
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FAISAL MASUD, FRCP</last_name>
    <role>Study Director</role>
    <affiliation>Principal SIMS/Services hospital lahore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>AMENA MIRZA, MRCP,FCPS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior registrar ,Services hospital lahore/SIMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madiha Fida, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>House Officer Services Hospital Lahore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology and Diabetes management centre</name>
      <address>
        <city>Lahore</city>
        <state>Punjab</state>
        <country>Pakistan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 15, 2013</lastchanged_date>
  <firstreceived_date>January 8, 2013</firstreceived_date>
  <firstreceived_results_date>March 7, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Services Institute of Medical Sciences, Pakistan</investigator_affiliation>
    <investigator_full_name>Prof. Faisal Masud</investigator_full_name>
    <investigator_title>Principal SIMS</investigator_title>
  </responsible_party>
  <keyword>Nitazoxanide,</keyword>
  <keyword>Sustained viral response</keyword>
  <keyword>Type 2 DIABETICS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
